Stocktoria
MANNKIND CORP MNKD
MANNKIND CORP (MNKD) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $349.0M at a 1.7% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: 0.82 — elevated (above the −1.78 line — aggressive-accounting signals worth a closer look) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.152 |
| Retained earnings / assets | -4.034 |
| EBIT / assets | 0.049 |
| Equity / liabilities | -0.061 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| MNKD | MANNKIND CORP | 3/9 | -11.89 | 218.2 | +22.2% |
| ARQT | Arcutis Biotherapeutics, Inc. | 4/9 | -3.68 | — | +91.3% |
| SVA | SINOVAC BIOTECH LTD | 3/9 | 8.06 | — | +6.8% |
| CRMD | CorMedix Inc. | 5/9 | 3.07 | 3.8 | +617% |
| EOLS | Evolus, Inc. | 2/9 | -8.65 | — | +11.6% |
| IRWD | IRONWOOD PHARMACEUTICALS INC | 4/9 | -11.97 | 28.3 | -15.7% |
| ESPR | Esperion Therapeutics, Inc. | 3/9 | -8.63 | — | +21.3% |
About MANNKIND CORP
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve glycemic control in adults with diabetes; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. Its products also include Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; FUROSCIX, a furosemide injection to treat fluid buildup in patients with chronic heart failure or chronic kidney disease. The company's pipeline of treatments for orphan lung diseases include MNKD-201, a dry-powder formulation of nintedanib for the treatment of idiopathic pulmonary fibrosis and MNKD-701. It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
FAQ
Is MNKD financially healthy?
MANNKIND CORP's Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does MNKD pay a dividend?
No, MANNKIND CORP does not currently pay a dividend.
How profitable is MNKD?
In FY2025, MANNKIND CORP had a net margin of 1.7%.
What is MNKD's P/E ratio?
MANNKIND CORP's trailing price-to-earnings (P/E) ratio is about 218.2×, based on its latest annual earnings.
What is the analyst price target for MNKD?
The average Wall-Street price target for MANNKIND CORP is $7.59, about 97.2% above the recent price, from 8 analysts.
Is MNKD a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on MANNKIND CORP: a Piotroski F-score of 3/9, an Altman Z″ in the distress zone, a P/E of about 218.2×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.